J. Goldman & Co’s MaxCyte MXCT Stock Holding History

J. Goldman & Co’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-175,000	Closed	-$866K	–	456
2023 Q1	$866K	Buy	+175,000	New	+$862K	0.04%	238

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

J. Goldman & Co's MXCT Position: Q2 2023 in Review

J. Goldman & Co sold out of MaxCyte (MXCT) in Q2 2023, closing a stake of 175,000 shares — an estimated $866K sold.

J. Goldman & Co first reported a position in MXCT in Q1 2023 and held it in 1 quarter. The position peaked at $866K in Q1 2023. 116 funds tracked by Wall St. Rank hold MXCT as of Q2 2023.

J. Goldman & Co reported no remaining MaxCyte position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 175,000 MaxCyte shares in Q2 2023, an estimated $866K.
J. Goldman & Co first reported a position in MaxCyte in Q1 2023 and held it in 1 quarter.
J. Goldman & Co's MaxCyte position peaked at $866K in Q1 2023.
116 funds tracked by Wall St. Rank held MaxCyte as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.